Role of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal Bartter syndrome

Kidney International

Volumn 62, Issue 1, 2002, Pages 253-260

  Reinalter, Stephan C ^a   Jeck, Nikola ^a   Brochhausen, Christoph ^a   Watzer, Bernhard ^a   Nüsing, Rolf M ^a   Seyberth, Hannsjörg W ^a   Kömhoff, Martin ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

COX 2; Hyperreninemia; Macula densa; Prostaglandin E2; Renin; Rofecoxib; Salt losing tubulopathy

Indexed keywords

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; INDOMETACIN; POTASSIUM CHANNEL; PROSTAGLANDIN E2; RENIN; ROFECOXIB;

ADOLESCENT; ADULT; ANTENATAL BARTTER SYNDROME; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MONITORING; DRUG SELECTIVITY; ENZYME ACTIVITY; FEMALE; HUMAN; HYPERPROSTAGLANDIN E SYNDROME; HYPERRENINEMIA; IN VITRO STUDY; KIDNEY TUBULE DISORDER; MALE; MUTATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; RENIN RELEASE; SCHOOL CHILD; SODIUM DEPLETION; URINARY EXCRETION;

EID: 0036318596     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2002.00435.x     Document Type: Article

References (48)

1. Bartter's syndrome, hypokalaemic alkalosis with hypercalciuria, is caused by mutations in the Na-K-2Cl cotransporter NKCC2
2. + channel, ROMK
3. Mutations in the gene encoding the inwardly-rectifying renal potassium channel, ROMK, cause the antenatal variant of Bartter syndrome: Evidence for genetic heterogeneity
4. Expression of the mouse Na-K-2Cl cotransporter, mBSC2, in the terminal inner medullary collecting duct, the glomerular, and extraglomerular mesangium, and the glomerular afferent arteriole
5. Localization of the ROMK protein on apical membranes of rat kidney nephron segments
6. Clinical presentation of gentically defined patients with hypokalemic salt-losing tubulopathies
7. Impaired response to furosemide in hyperprostaglandin E syndrome: Evidence for a tubular defect in the Loop of Henle
8. Congenital hypokalemia with hypercalciuria in preterm infants: A hyperprostaglandinuric tubular syndrome different from Bartter syndrome
9. Mutation of BSND causes Bartter syndrome with sensorineural deafness and kidney failure
10. - reabsorption and inner ear K+ secretion
11. Bartter syndrome with sensorneural deafness due to disturbed activation of CIC chloride channels by parttin
12. Infantile variant of Bartter syndrome and sensorineural deafness: A new autosomal recessive disorder
13. Hypokalemic salt-losing tubulopathy with chronic renal failure and sensorineural deafness
14. Bartter's syndrome with hyperplasia of renomedullary cells: Successful treatment with indomethacin
15. Bartter's syndrome: A disorder characterized by high urinary prostaglandins and a dependence of hyperreninemia on prostaglandin synthesis
16. Hypokalaemic tubular disorders: The hyperprostaglandin E syndrome and the Gitelman-Bartter syndrome
17. Arachidonic acid metabolites and the kidney
18. Mechanism of action of nonsteroidal anti-inflammatory drugs
19. Prostaglandin synthase 2
20. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction
21. Cloning, expression, and regulation of rabbit cyclooxygenase-2 in renal medullary interstitial cells
22. Cyclooxygenase-2-selective inhibitors impair glomerulogenesis and renal cortical development
23. Acute upregulation of COX-2 by renal artery stenosis
24. Furosemide stimulates macula densa cyclooxygenase-2 expression in rats
25. Cyclooxygenase-2 expression is associated with the renal macula densa of patients with Bartter-like syndrome
26. Pathogenetic role of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal Bartter syndrome: Therapeutic use of COX-2 inhibitor nimesulide
27. New treatment options for Bartter's syndrome
28. Relation between plasma concentration of indomethacin and its effects on prostaglandin synthesis and platelet aggregation in man
29. Determination of seven prostanoids in 1 ml of urine by gas chromatography-negative ion chemical ionization triple stage quadrupole mass spectrometry
30. Quantification of the major urinary metabolite of the E prostaglandins by mass spectrometry: Evaluation of the method's application to clinical studies
31. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2
32. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases
33. Differential inhibition of human prostaglandin endoperoxide synthase-1 and -2 by nonsteroidal anti-inflammatory drugs
34. High-speed liquid chromatographic analysis of indomethacin in plasma
35. Determination of rofecoxib (MK-0966), a cyclooxygenase-2 inhibitor, in human plasma by high-performance liquid chromatography with tandem mass spectrometric detection
36. Synthesis and biological activaty of 2,3- and 3,4-diarylfurans and 2,3,4-triaryl-2,5-dihydrofurans
37. Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans
38. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse
39. Neonatal end-stage renal failure associated with maternal ingestion of cyclooxygenase-type-2 selective inhibitor nimesulide as tocolytic
40. Cyclooxygenase-2 mediates increased renal renin content induced by low-sodium diet
41. Regulation of cyclooxygenase expression in the kidney by dietary salt intake
42. Renin expression in COX-2-knockout mice on normal or low-salt diets
43. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects
44. Low chloride stimulation of prostaglandin E2 release and cyclooxygenase-2 expression in a mouse macula densa cell line
45. Role of p38 in the regulation of renal cortical cycooxygenase-2 expression by extracellular chloride
46. Cellular control of renin secretion
47. Prostaglandin E receptors and the kidney
48. Regulation of renin: New evidence from cultured cells and genetically modified mice